Company · founded 1995
Autoimmune Technologies (United States)
New Orleans, United States · autoimmune.com
- Citations, last 5 years
- 0
- Works, last 5 years
- 3
- h-index
- 30
- Scientists listed
- 0
- Grants since 2016
- 9
Grants received
2022–2025 · research · R43
Strategy for specific delivery of antisense oligonucleotides to T cells
Gaddiel Galarza-Munoz · Autoimmune Technologies (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Development of antisense oligonucleotides that enhance sIL7R as novel cancer immunotherapy
Gaddiel Galarza-Munoz · Autoimmune Technologies (United States) · funded by National Institutes of Health
2020–2022 · research · R41
Determination of optimal antisense oligonucleotide chemistry for efficient and safe splicing modulation in T cells
Gaddiel Galarza-Munoz · Autoimmune Technologies (United States) · funded by National Institutes of Health
2019–2024 · research · R42
Development of a novel accurate therapy for multiple sclerosis
Gaddiel Galarza-Munoz · Autoimmune Technologies (United States) · funded by National Institutes of Health
2019–2025 · research · R42
Development of a novel accurate therapy for multiple sclerosis
Gaddiel Galarza-Munoz · Autoimmune Technologies (United States) · funded by National Institutes of Health
2019–2020 · research · R41
Development of a novel accurate therapy for Multiple Sclerosis
Gaddiel Galarza-Munoz · Autoimmune Technologies (United States) · funded by National Institutes of Health
2019–2020 · research · R43
Novel accurate therapy for Multiple Sclerosis: Optimization of antisense oligonucleotides delivery and functionality in primary T cells
Gaddiel Galarza-Munoz · Autoimmune Technologies (United States) · funded by National Institutes of Health
2018–2020 · research · R41
Double Chimeric Peptide Vaccine Feasible for Human Use that Protects against Disseminated Candidiasis caused by medically important Candida species
Hong Xin · Autoimmune Technologies (United States) · funded by National Institutes of Health
2017–2019 · grant · PRMRP
Development of an Immunotherapeutic Delivery Platform Using Adipose-Derived Mesenchymal Stem Cells
Russell Wilson · Autoimmune Technologies (United States) · funded by Congressionally Directed Medical Research Programs